ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31

Anixa Biosciences Inc

Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026

$2.61−0.06 (-2.25%)

Close on Oct 19, 2026

Market cap: $89.22M
P/E (TTM): –
Dividend yield: –

Anixa Biosciences Inc income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-10-31	FY 2024 2024-10-31	FY 2023 2023-10-31	FY 2022 2022-10-31	FY 2021 2021-10-31	FY 2020 2020-10-31	FY 2019 2019-10-31	FY 2018 2018-10-31	FY 2017 2017-10-31	FY 2016 2016-10-31	FY 2015 2015-10-31	FY 2014 2014-10-31	FY 2013 2013-10-31	FY 2012 2012-10-31	FY 2011 2011-10-31	FY 2010 2010-10-31
Revenue	–	0.21	0.21	–	0.51	–	0.25	1.11	0.36	0.30	9.26	3.67	0.39	0.94	1.00	0.73
Cost of Revenue	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00	0.03	0.08
Gross Profit	–	–	–	–	–	–	–	–	–	–	–	–	–	0.94	0.97	0.65
Research & Development	5.07	6.40	4.77	6.70	6.19	4.38	5.47	6.81	1.60	1.56	0.71	–	–	2.21	3.12	3.01
Selling, General & Admin	–	–	–	–	–	–	5.66	6.91	4.41	2.71	5.51	6.41	7.99	2.86	2.87	2.89
General & Administrative	6.63	7.44	6.29	7.17	7.07	5.60	5.66	–	–	–	–	–	–	–	–	–
Total Costs & Expenses	12	14	11	14	14	9.98	12	15	6.44	4.81	10	8.71	8.31	5.07	6.03	5.98
Operating Income	-12	-14	-11	-14	-13	-9.98	-12	-14	-6.08	-4.51	-0.94	-5.04	-7.92	-4.13	-5.03	-5.25
Interest Expense	–	–	–	–	–	–	–	–	0.50	0.52	0.45	1.26	1.11	0.01	–	–
Interest & Investment Income	0.67	1.13	1.08	0.10	0.00	0.03	0.07	0.05	0.02	0.01	0.02	0.01	0.00	0.00	0.00	0.00
Gain (Loss) on Sale of Assets	–	–	–	–	0.01	0.15	–	–	-0.05	–	-0.01	–	–	–	–	–
Legal Settlements	–	–	-0.21	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	–	–	–	–	–	–	-12	-14	-5.01	-5.02	-1.38	-9.61	-10	-4.25	-6.78	-5.18
Income Tax Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.60	–
Net Income incl. Noncontrolling Interests	-11	-13	-9.93	-14	-13	-10	-12	-14	-5.01	-5.02	–	–	–	–	–	–
Minority Interest in Earnings	-0.10	-0.14	-0.12	-0.18	-0.17	-0.07	-0.17	-0.25	–	–	–	–	–	–	–	–
Net Income	-11	-13	-9.81	-14	-13	-10	-12	-14	-5.01	-5.02	-1.38	-9.61	-10	-4.25	-7.38	-5.18
Preferred Dividends	–	–	–	–	–	–	–	–	2.01	–	–	–	–	–	–	–
Net Income to Common	–	–	–	–	–	–	-12	-14	-7.02	–	–	–	–	–	–	–
EPS (Basic)(per share)	-0.34	-0.39	-0.32	0.45	-0.45	-0.45	-0.59	-0.79	-0.58	-0.57	-16.00	-1.10	-1.25	-0.50	-1.00	-0.75
EPS (Diluted)(per share)	-0.34	-0.39	-0.32	0.45	-0.45	-0.45	-0.59	-0.79	-0.58	-0.57	-16.00	-1.10	-1.25	-0.50	-1.00	-0.75
Shares Outstanding (Basic, Weighted)(shares)	0.03	0.03	0.03	0.03	29	22	20	18	12	8.74	8.76	8.71	7.87	7.27	6.67	–
Shares Outstanding (Diluted, Weighted)(shares)	0.03	0.03	0.03	0.03	29	22	20	18	12	8.74	8.76	8.71	7.87	7.27	6.67	–
EBITDA	–	–	–	–	–	–	–	-14	-6.03	-4.48	-0.93	–	–	-4.13	-5.02	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -62.2%

Financial strength

Current ratio: 8.54
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 80.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 6.17
Dividend yield: –